OVERVIEW
The Life Sciences & Healthcare industry is witnessing a dramatic transformation, and
“convergence” has emerged as a pivotal focalpoint. Convergence of the entire ecosystem,
including pharmaceutical companies, payers, providers, and other intermediaries with the patient
at the center, is driving this journey. There is a definite shift from the outdated
fee-for-service models to a more patient-centric, value-based, and affordable one.
The players in the ecosystem are constantly on the lookout for making meaningful
and creative use of technology to bring together applications, infrastructure, and IoT enabled
devices. They strive to offer unique and digital solutions to patients, ensuring a seamless and
affordable healthcare experience.
For the last 10 years, we have been a ‘partner of choice’ for leading Life Sciences & Healthcare
companies. Our clients include 10 of the top 20 pharmaceutical companies and seven leading
medical devices firms. We believe that convergence of the ecosystem is the future and are
consequently working to create unique customer experiences. This involves innovative
orchestration of holistic and end-to-end offerings, including IoT, Digital, Analytics,
Applications, and Cloud services.
Life Sciences enterprises are looking towards technology companies to understand how creatively
they can deploy next gen avenues, including:
- Automation, application modernization, and infrastructure landscape to make it lean and
agile with an optimized cost blueprint
- Advanced, predictive, and prescriptive analytics to generate meaningful insights that
facilitate decision making
- Digital strategies leveraging IoT, Digital, and SMAC technologies for
building highly
scalable Connected Digital Health Platforms, which ensure better patient/care-giver
connectivity, issue resolution, adherence level improvements, and enhanced brand value and
market share.
We realize that these challenges have not changed over the last decade. They
differ based on the specific growth cycle of the companies.
For instance, Life Sciences companies in the low growth phase of the industry
life cycle, due to patent expiry, would emphasize on reducing operational expenses. However, a
pharmaceutical company in the high growth stage would focus on patient
centricity/disease-management, launch excellence, and market access.